MedPath

RAFF5 Proposal: Improve the Quality and Safety of Patients Seen in the Emergency Department for Acute Atrial Fibrillation and Flutter

Completed
Conditions
Atrial Fibrillation
Atrial Flutter
Interventions
Other: Checklist implementation
Registration Number
NCT05468281
Lead Sponsor
Ottawa Hospital Research Institute
Brief Summary

Acute atrial fibrillation (AF) and flutter (AFL) are the most common arrhythmias requiring management in the emergency department (ED). They are characterized by sudden onset of a rapid heart rate which may be irregular (AF) or regular (AFL). Our focus is on episodes of acute AF or AFL which are usually less than 48 hours in duration and are highly symptomatic, requiring rapid treatment in the ED. Management guidelines for acute AF/AFL have changed substantially in recent years with several recent revisions published by the Canadian Cardiovascular Society (CCS) and the Canadian Association of Emergency Physicians (CAEP). The 2021 CAEP Acute Atrial Fibrillation/Flutter Best Practices Checklist (CAEP Checklist) was very recently published to assist ED physicians in Canada and elsewhere manage patients who present to the ED with acute AF/AFL (Figure 1).

The overall goal of this project is to improve the quality and safety of the immediate and subsequent care of patients seen in the ED with acute AF and AFL by implementing the principles of the CAEP Checklist at both The Ottawa Hospital (TOH) EDs and by working with TOH cardiologists to provide rapid cardiology follow-up processes for patients discharged from the ED. The Investigators propose a before-after cohort study using an interrupted time series design to evaluate implementation involving 720 patients at the two TOH EDs over a 24-month period.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1108
Inclusion Criteria
  • include all eligible patient visits to the participating EDs during the study period regardless of how they are managed.
  • include stable patients aged 18 and over,
  • presenting with an episode of acute AF or AFL of at least 3 hours duration,
  • where symptoms require ED management by rhythm or rate control.
Read More
Exclusion Criteria
  • The study will exclude patients who have any of:

    1. permanent AF;
    2. deemed unstable and required immediate electrical cardioversion; or
    3. primary presentation was for another condition rather than arrhythmia.
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
After PeriodChecklist implementationThe after period (12 months) will be when patients are prospectively enrolled, and outcomes assessed.
Primary Outcome Measures
NameTimeMethod
Improve the quality and safety of ED management of AF and AFL14 day

the quality and safety of ED management based upon the CAEP Checklist management. best practices. The study team will use a score sheet which will identify specific managements for AF and AFL that are 1) optimal; 2) suboptimal; 3) unsafe.

Secondary Outcome Measures
NameTimeMethod
Use of cardioversion (chemical or electrical) in the EDDuration of the ED visit, approximately 4-12 hours.
prescription of OAC on dischargeDuration of the ED visit, approximately 4-12 hours.

Whether or not they were given an outpatient prescription for oral anticoagulants in accordance with the 2021 CAEP Checklist

use of rate control and the final heart rate at dispositionDuration of the ED visit, approximately 4-12 hours.
Adverse events attributable to medical managementDuration of the ED visit, approximately 4-12 hours.

adverse events including: i) conduction problems; ii) dysrhythmias; iii) hypotension requiring treatment; iv) respiratory events; f) admission to a hospital unit; and g) use of the rapid referral process.

consultations done in the ED by cardiologyDuration of the ED visit, approximately 4-12 hours.

Whether or not the patient had an (unnecessary) consultation done in the ED by cardiology

Trial Locations

Locations (1)

Ottawa Hospital Research Institute

🇨🇦

Ottawa, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath